Boston Scientific touts Promus Element China stent data; Stryker hip lawsuit will proceed;

 @FierceMedDev: If you missed our special report yesterday: Med Tech's 2012 R&D big spenders. More | Follow @FierceMedDev

 @MarkHFierce: Big win for GE - expanded FDA approval for an imaging agent, now to gauge risk of death in heart failure patients. Release | Follow @MarkHFierce

 @DamianFierce: Feds: The worry about device tax/regulatory slowdown for mobile apps is mostly hot air. More | Follow @DamianFierce

> Boston Scientific ($BSX) generated encouraging data from its PLATINUM China trial, which evaluated the safety and effectiveness of its Promus Element drug-eluting platinum chromium coronary stent system.  Release

> A U.S. appeals court sided with the FDA, ruling the agency correctly denied fast-track approval for two of Cytori Therapeutics' stem cell-related medical devices. Story

> Greatbatch plans to develop complete medical devices rather than just device components and subassemblies. Story

> A personal injury lawsuit over Stryker's ($SYK) Trident hip implant will proceed, a Massachusetts federal judge has ruled. Story

> Sensors on Seniors has changed its name to RFMED Solutions. The company's initial claim to fame is a wireless sensor system designed to help caregivers monitor elderly patients to help them avoid bed sores or falls, or stop wandering. Story (sub. req.)  

> Technion-Israel Institute of Technology highlighted some major home-grown medical device innovations during President Barak Obama's Israel visit, including the ReWalk robotic exoskeleton suit marketed by Argo Medical. Story

> iTraumaCare won a CE marking for its debut product--a new clamp to address massive hemorrhages. Release

Biotech News

 @FierceBiotech: Cerulean Pharma's lead nanodrug crashes in lung cancer study. News | Follow @FierceBiotech

@JohnCFierce: No decision yet, but Soriot at AstraZeneca certainly sounds like he's going to do a biosimilars move. More | Follow @JohnCFierce

@RyanMFierce: No surprises here. BG-12 gets nod from EMA committee as first-line MS therapy. Release | Follow @RyanMFierce

> Titan claims victory for anti-addiction drug after mixed FDA panel votes. Report

> Genzyme boasts of durable response to MS drug Lemtrada. Story

> Report: CRO with a scandal-plagued past shuts down, leaving patients stranded. Article

Pharma News

@FiercePharma: Vietnam drug spending makes it a prime pharma target. Article | Follow @FiercePharma

@EricPFierce: Inspection report details why Hospira's hopes were recently dashed by the FDA. Story | Follow @EricPFierce

> EMA recommendation gives Sanofi's MS drug Aubagio another boost. More

> J&J fights $327M Risperdal verdict, saying no one was harmed. Story